Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines in adults.[8][6] It is given by injection under the skin.[8][6]
The most common side effect is pain and redness at the site of injection.[8] Other side effects include allergic reactions.[8] It is in the calcitonin gene-related peptide antagonist class of medications.[8]
It was approved for medical use in the United States in 2018,[8] the European Union in 2019,[7] the UK in 2020[4] and Argentina by September 2021.[9]
^"Fremanezumab (Ajovy) Use During Pregnancy". Drugs.com. 3 October 2018. Retrieved 2 April 2020.
^"Summary Basis of Decision (SBD) for Ajovy". Health Canada. Retrieved 29 May 2022.
^"Ajovy Product information". Health Canada. Retrieved 31 May 2022.
^ ab"Fremanezumab". NICE - National Institute for Health and Care Excellence. Retrieved 25 June 2021.
^"Ajovy (fremanezumab) 225 mg Pre-filled Syringe for Injection - Summary of Product Characteristics (SmPC)". (emc). Retrieved 27 September 2021.
^ abc"Ajovy- fremanezumab-vfrm injection". DailyMed. U.S. National Library of Medicine. 5 February 2020. Retrieved 2 April 2020.
^ ab"Ajovy EPAR". European Medicines Agency (EMA). 29 January 2019. Retrieved 2 April 2020.
^ abcdef"Fremanezumab-vfrm Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 15 July 2019.
^"Migraña: en qué consiste el nuevo tratamiento para esta enfermedad frecuente e incapacitante". 12 September 2021.
Fremanezumab, sold under the brand name Ajovy, is a medication used to prevent migraines in adults. It is given by injection under the skin. The most common...
associated with Huntington's disease and tardive dyskinesia; and Ajovy (fremanezumab), used for the preventive treatment of migraine in adults. Additional...
public domain. Spreitzer H (3 July 2017). "Neue Wirkstoffe: Galcanezumab, Fremanezumab und Eptinezumab". Österreichische Apothekerzeitung (in German) (14/2017)...
and developer of the pain medicine tanezumab, the migraine medicine fremanezumab, the Alzehimer's drug ponezumab and the target for the basal cell carcinoma...
demonstrating reduced cluster attack burden after a 3-dose pulse of psilocybin. Fremanezumab, a humanized monoclonal antibody directed against calcitonin gene-related...
blockers were approved by the FDA for the prevention of migraine: erenumab; fremanezumab; and galcanezumab. The calcitonin gene-related peptide (CGRP) is a therapeutic...
antibody against beta amyloid for the treatment of Alzheimer's disease Fremanezumab (codenamed TEV-48125, RN307 and LBR-101), a monoclonal antibody against...
S; Ahn, K; Kirsch, J; Hoskin, JL (2023). "Review of Tolerability of Fremanezumab for Episodic and Chronic Migraine". Neuropsychiatric Disease and Treatment...
anti-calcitonin gene-related peptide, including eptinezumab, erenumab, fremanezumab, and galcanezumab, appear to decrease the frequency of migraines by one...
Yang, Ronghua; Ma, Yuju; Aycardi, Ernesto (15 May 2018). "Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized...
Global Information